Introduction
Heart failure (HF) with preserved ejection fraction (HFpEF) is a global public health crisis, responsible for a high burden of mortality and morbidity, and becoming the dominant form of HF in ageing populations.
1 -3 The high burden of cardiovascular risk factors across the Asian continent are forewarning signs of an impending epidemic of HFpEF in Asia. To date, very limited data are available on the Asian HFpEF phenotype. Prior epidemiologic studies in Asia were either small single-centre studies or focused exclusively on a single country. 4 -12 We aimed to describe baseline clinical and echocardiographic characteristics of patients with HFpEF in the prospective multinational Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry, which is the first pan-Asian registry collecting data on HF in Asia. Furthermore, recognizing that regional differences in HFpEF have been described in global clinical trials, 13 we compared the characteristics of patients from different geographic regions within Asia, and of different Asian ethnicities. Furthermore, we studied differences between Asian patients with HFpEF and patients with HFpEF from Western populations. We hypothesized that the Asian HFpEF phenotype may have unique characteristics (in contrast to the previously described Western phenotype), and that regional and ethnic differences in HFpEF may exist between Asian and Caucasian populations with HFpEF and within Asia. Such findings would provide novel insights for future trial design and health care resource allocation.
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Methods
The ASIAN-HF registry was originally designed to include only patients with HF and reduced ejection fraction (HFrEF) (ejection fraction <40%), 15, 16 but in 2013, a protocol amendment also included patients with HFpEF (ejection fraction ≥50%). In short, the ASIAN-HF registry is a multi-national registry of Asian HF patients involving 46 medical centres across 11 Asian regions (Hong Kong, Taiwan, China, Japan, Korea, India, Malaysia, Thailand, Singapore, Indonesia, Philippines). Site profiles are presented in the online supplementary Table S1. All recruitment sites had cardiology and HF specialty units and had considerable experience with following and treating chronic HF patients. Inclusion criteria for the HFpEF study were > 18 years of age with symptomatic HF (at least one episode of decompensated HF in the previous months resulting in a hospital admission or treatment in an outpatient clinic) with a left ventricular ejection fraction (LVEF) of ≥50% according to the 2012 European Society of Cardiology (ESC) guidelines. 17 Patients were excluded if they had severe valvular heart disease as a cause of HF, a life-threatening co-morbidity with a life expectancy <1 year, or if they were unable or unwilling to give consent. Additionally, patients enrolled in a concurrent clinical therapeutic trial were excluded. Data on demographics, previous medical history, clinical symptoms and functional status were collected. According to the protocol, patients underwent standard 12-lead electrocardiogram (ECG) and transthoracic echocardiography at baseline.
Study definitions
The definitions of common risk factors in HF have previously been described. 15 . Coronary artery disease (CAD) was defined as angiographically documented presence of significant coronary obstruction, history of myocardial infarction or prior revascularization. Hypertension was defined as the clinical diagnosis (blood pressure ≥ 140/90 mmHg) and receiving anti-hypertensive therapy. Diabetes was defined as the presence of the clinical diagnosis (fasting plasma glucose ≥7 mmol/L or random plasma glucose ≥11.1 mmol/L, or glycated haemoglobin ≥6.5%) and/or receiving anti-diabetic therapy. Chronic kidney disease (CKD) was determined using a cutoff point for the estimated glomerular filtration rate (eGFR) at <60 mL/min/1.73 m 2 . 18 The eGFR was calculated using the Modification of Diet in Renal Disease study equation. Chronic obstructive pulmonary disease (COPD) was based on medical history. Anaemia was defined according to the WHO criteria of haemoglobin <13 g/dL for men and < 12 g/dL for women. A previous hospitalization for HF was defined as any previous hospitalization for HF in the 6 months before inclusion requiring intravenous or oral diuretic treatment. Regions were grouped according to geographic regions based on the United Nations Regional Groups 15 -Northeast Asia (South Korea, Japan, Taiwan, Hong Kong, and China); South Asia (India); Southeast Asia (Thailand, Malaysia, Philippines, Indonesia, and Singapore). Ethnicity was defined as self-reported ethnicity and grouped according to Chinese, Indian, Malay, Japanese/Korean and other. ECG rhythm was defined as sinus, atrial fibrillation (AF)/flutter or other, of which the latter includes heart block, junctional rhythm, paced rhythm, sick sinus syndrome, ventricular fibrillation, tachycardia, and unknowns.
Echocardiography
The collection and processing of echocardiographic data have previously been described. 15 Each centre performed transthoracic echocardiography exams according to internationally accepted guidelines. 19 These assessments included measurements of LVEF and left ventricular (LV) dimensions, left atrial dimensions, LV diastolic function, stroke volume, and cardiac output. The Cardiovascular Imaging Core laboratory of the National University Health System, Singapore, provided oversight and imaging protocol guidelines for quality assurance of echocardiograms. Accuracy and reproducibility of interpreted results were ensured through consistent training and systematic analytical processes provided by the Core Laboratory according to international guidelines. 19 Left ventricular mass (LVM) was calculated from linear dimensions and indexed to body surface area (BSA), according to guidelines. 19 Relative wall thickness (RWT) was calculated by the formula [(2 x posterior wall thickness in diastole)/LV diastolic internal diameter. LV hypertrophy (LVH) was determined as LVM indexed to BSA >115 g/m 2 in men and > 95 g/m 2 in women. Normal LV geometry was defined as having no LVH and a RWT ≤0.42. Abnormal LV geometry was classified as concentric remodelling (no LVH and RWT >0.42), concentric hypertrophy (LVH and RWT >0.42) and eccentric hypertrophy (LVH and RWT ≤0.42). Left atrial size was also indexed to BSA. 19 Additionally, we examined the percentage of patients satisfying objective echocardiographic criteria for diastolic dysfunction; namely structural [LVH or left atrial enlargement (left atrial volume indexed to BSA >34 mL/m 2 )] or functional (E/e' ≥ 13 or mean e' septal/lateral wall <9 cm/s) alterations, according to the 2016 ESC guidelines. 20 Additional sensitivity analyses were provided according to the updated definition of diastolic dysfunction. 21 
Outcomes
In total, 1111 (92%) patients had outcomes data available, whereas 92 (8%) patients were lost to follow-up. Patients with less than 1-year outcomes available were censored at their last known visit date. Outcomes were adjudicated by an independent committee. All data were captured prospectively in an electronic database, with registry operations and data management handled by quintiles outcomes as the contract research organization appointed by the academic executive committee.
Ethics
Ethics approvals were obtained from the relevant human ethics committees at all sites. All patients included provided informed consent and this study adheres to the principles of medical research as laid down in the Declaration of Helsinki.
Statistical analysis
We performed baseline descriptive statistics according to region (Northeast Asia, Southeast Asia, and South Asia) as well as according to ethnicity (Chinese, Indian, Malay, Japanese/Korean, and other). Data are presented as means ±standard deviation, medians and interquartile range (IQR), or numbers and percentages. Differences between groups were tested with one-way analysis of variance (ANOVA), Kruskal-Wallis test, or the chi-square test, as appropriate. Correction for multiple testing was performed using the Benjamini-Hochberg correction, with a false discovery rate of 0.05. Further associations of co-morbidities across regions and ethnicities were tested using logistic regression with the co-morbidity as the dependent variable. Analyses were then further corrected for age, sex, BMI, enrolment type (inpatient vs. outpatient), and previous hospitalization for HF.
When examining the relationship between LVH and RWT and ethnicity, logistic regression was used. Here, LVH and remodelling (RWT ≤0.42 vs. RWT >0.42) were used as dependent variables with ethnicity as the independent variable with the Chinese as the reference category. The associations between ethnicity and region with outcome were corrected for age, sex, enrolment type (outpatient vs. inpatient), previous HF hospitalization, New York Heart Association (NYHA) class, history of diabetes, AF, CAD, and hypertension. Additionally, we have provided analyses correcting for differences in LVM indexed to BSA on top of the aforementioned confounders. In secondary analyses, we investigated the association between ethnicity and region and all-cause mortality or hospitalization for HF alone. In the latter case, all-cause mortality was used as a competing risk. Due to fewer events, we used a reduced model for these secondary analyses consisting of age, sex, enrolment type and previous hospitalization for HF. All tests were performed two-sided and P-values of <0.05 were considered statistically significant. Statistical analyses were performed with STATA 13.0 (Stata Corp., College Station, TX, USA). ; 34% were overweight, 26% obese, and 3% underweight. The majority (59%) of patients were in NYHA class II, while 24% were in NYHA class III/IV. The mean systolic blood pressure was 132 ±22 mmHg. The most common presenting signs and symptoms of HF were shortness of breath on exertion (59.7%) and a reduction in exercise tolerance (58.5%). Co-morbidities were highly prevalent: 70% of patients had ≥2 co-morbidities, most commonly hypertension (71%), followed by anaemia (57%), CKD (50%), diabetes (45%), CAD (29%), a history of AF (29%), and obesity (26%). Natriuretic peptides were available in a subset of 455 patients and in 90% of these the values were above the guideline-recommended cutoff points, with no differences between geographical regions (P = 0.261). When restricting analyses to patients without AF, no difference was observed between regions in the proportions of patients above the guideline specified cutoff points for natriuretic peptides. Median N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were highest in patients from South Asia, but differences between regions were attenuated after correcting for age (P > 0.1 for all). The baseline ECG showed AF in 23.6% of the cases with a mean QRS duration of 97.8 ms and a left bundle branch block in 3.3% of the patients. Medications included diuretics in 70.9%, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) in 66.4%, beta-blockers in 67.7%, and mineralocorticoid receptor antagonists (MRAs) in 21.5% of all patients.
Results
Overall cohort characteristics
Patient characteristics and echocardiographic parameters by region
Characteristics of patients by region are presented in Table 1 . Patients from South Asia were the youngest, and those from Northeast Asia were the oldest (mean age in South Asians: 63.4 ±12.5 years vs. Southeast Asians: 67.4 ±11.6 years vs. Northeast Asians: 71.6 ±11.7 years, P < 0.001). Presenting systolic blood pressure was lowest in Northeast Asians (131 ±21 mmHg) and highest in Southeast Asians (135 ±24 mmHg, P = 0.021). Mean BMI was lowest in Northeast Asians (25.7 ±5.5 kg/m 2 ) and highest in Southeast Asians (28.2 ±6.2 kg/m 2 ; P < 0.001). Symptoms of dyspnoea at rest, orthopnoea, elevated jugular venous pressure, peripheral oedema and pulmonary rales were significantly more prevalent in Southeast Asians than South Asians and Northeast Asians. Overall medication usage of ACE inhibitor/ARB, beta-blockers and diuretics was lowest in South Asians and highest in Southeast Asians.
Hypertension was most common in Southeast Asians (82.9%) and least common in South Asians (40.3%) ( Figure 1) . CAD was most common in Southeast Asians (36.7%) and least common in South Asians (22.9%). CKD was most common in Southeast Asians (60.4%) followed by Northeast (44.3%) and South Asians (41.3%) (P < 0.001) ( Figure 1) . Anaemia was present in 57.4% of the total cohort, with highest prevalence in South Asians (60.0%) and Southeast Asians (63.6%) (P = 0.002) ( Figure 1 ). Highest rates of obesity (BMI ≥30 kg/m 2 ) were found in South Asia (36.2%) and the lowest rates in Northeast Asia (16.5%; P < 0.001).
In the overall cohort, the median LVEF was 60% (IQR 55-65%), LV end-diastolic volume was 94 (IQR 73-121) mL, LV end-systolic volume was 37 (IQR 27-52) mL, left atrial volume indexed to BSA was 34 (IQR 24-49) mL/m 2 and mitral E/e' was 15.5 (IQR 11.8-20.5). In sensitivity analyses, 99.5% of patients satisfied the 2016 ESC criteria for diastolic dysfunction (E/e' ≥ 13, E' medial/lateral <9 ms, left atrial enlargement or LVH). In sensitivity analyses using the 2016 Nagueh definition of diastolic dysfunction, 21 there was no difference in the prevalence of diastolic dysfunction among regions (P = 0.247). Since the definition of diastolic dysfunction in patients with AF can be problematic, we performed additional sensitivity analyses restricting to patients with no AF on ECG at time of echocardiography. In this subgroup, 99% of patients had diastolic dysfunction according to the 2016 ESC HF criteria, 20 with no difference between regions (P = 0.153). This percentage did not differ between regions (P = 0.230) or countries (P = 0.970). Examined by region ( 
Patient characteristics and echocardiographic parameters by ethnicity
When examining differences between ethnicities, patients of Japanese/Korean (69.8 ±12.9 years) and Chinese (71.6 ±11.2 years) ethnicity were considerably older (P < 0.001) than patients of Malay (63.3 ±10.9 years) or Indian (63.9 ±12.4 years) ethnicity ( Table 3) . Mean BMI was lowest in Japanese (24.2 ±6.3 kg/m 2 ) and highest in Malays (30.5 ±7.0 kg/m 2 ; P < 0.001). Systolic blood pressure was highest in Malays (137 ±26 mmHg) and lowest in Japanese/Koreans (121 ±20 mmHg). ACE inhibitor/ARB were most often used by Chinese (71.3%) patients, while 82.3% of Japanese/Korean patients were on beta-blockers. MRA usage was highest in Japanese/Korean patients (39.5%).
Compared to Chinese, Indians had lower odds of hypertension [odds ratio (OR) 0.18, 95% confidence interval (CI) 0.12-0.26] and diabetes (OR 0.58, 95% CI 0.41-0.83) when adjusting for age, sex, BMI, enrolment type and previous hospitalization for HF. In similar multivariable analyses, Japanese/Korean patients were at lower odds for hypertension, diabetes, CAD, obesity, CKD and obesity (P < 0.05 for all), yet these patients had comparatively high rates of AF (55%) compared to other ethnicities. Regarding echocardiographic parameters, Japanese/Koreans had higher LV volumes compared to other ethnicities (P < 0.001) ( ] ethnicity (P = 0.006). RWT was highest in Indians and Malays. E/e' did not differ among ethnicities (P = 0.230). Left atrial volume index was higher in Chinese and Japanese/Koreans and lowest in Indians. Overall, Japanese/Koreans had more eccentric hypertrophy, while Indians and Malays had more concentric hypertrophy ( Figure 2B) . Adjusting for age, sex and co-morbidities, patients of Indian ethnicity (OR 0.4, 95% CI 0.2-0.7) less often had LVH compared to Chinese patients ( Figure 3A) but had relatively more concentric remodelling (OR 4.4, 95% CI 2.1-9.1) ( Figure 3B ).
Outcomes
Among 891 (74%) patients who completed 1-year follow-up, 129 (14.5%) died or were hospitalized for HF. Rates of adverse events ( Figure 4A) 
Discussion
This is the first prospective multi-national study of patients with HFpEF across Asia. Asian patients with HFpEF were relatively young (with more than a third under the age of 65 years) and lean (with only a fifth being obese) compared to those from Western populations; yet they carried a high co-morbidity burden (70% of patients had ≥2 co-morbidities). There were striking regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia: South Asians were the youngest and more often obese but had the lowest prevalence of . AF despite the most concentric LV hypertrophy. Southeast Asian patients were only slightly older, yet had the highest prevalence of all co-morbidities (except AF), the most LVH and the worst outcomes. Northeast Asians were the oldest and had the most AF and eccentric LV hypertrophy. In terms of ethnicity, Indian and Malay patients with HFpEF were considerably younger than Chinese and Japanese/Korean patients. Despite their relative youth, Malay patients with HFpEF had very high rates of obesity, diabetes, CKD and anaemia, and the worst outcomes among the ethnicities. These regional and ethnic differences have important implications for public health measures and global HFpEF trial design. Values are expressed as mean ±standard deviation, number (%), or median (interquartile range). ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy-defibrillation; eGFR, estimated glomerular filtration rate; HF, heart failure; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NA, not available; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association. * Significant after correction for multiple comparisons using a false discovery rate of 0.05.
Figure 3 Forest plots depicting the relationship between ethnicity and left ventricular hypertrophy (LVH) (A) and relative wall thickness (B)
corrected for age, sex and co-morbidities.
The younger age of Asian patients with HFpEF is consistent with prior data. The ADHERE Asia Pacific registry previously showed that Asian patients were considerably younger, with lower rates of CAD and AF compared to their American counterparts from the US ADHERE registry; however, data specifically on HFpEF were not available. 22 Other prior studies on HFpEF in Asia were largely confined to single country or centres. In Northeast China, Guo et al. 23 found that the prevalence of HFpEF was 3.5% among the general population and that these patients had higher rates of obesity and hypertension. A single centre study of purely hospitalized patients from Hong Kong reported that patients with HFpEF had a mean age of 77 and a 1-year all-cause . mortality rate of 12.5% 24 -these characteristics are similar to the hospitalized subset of ASIAN-HF from Hong Kong. Our current findings therefore confirm and extend prior data to a prospective multi-national setting. The consistency with prior single nation data also provides reassurance that potential bias from site selection in our study may not have substantially impacted the results. A single centre study from the Kumamoto region, Japan, showed that patients with HFpEF from Japan were considerably younger, yet had a similar prevalence of hypertension compared to their Western counterparts. This was further corroborated by findings from the CHART-2 study. 25 Despite this striking difference in age, overall rates of key co-morbidities such as hypertension, diabetes A B Figure 4 Rates of all-cause mortality and heart failure (HF)-related hospitalization at 1-year of follow-up across regions (A) and ethnicities (B).
mellitus and CKD, were similar between our patients with HFpEF from ASIAN-HF and Western patients with HFpEF ( Table 5) . Rates of some co-morbidities were even higher among our relatively young Asian patients; for example, Southeast Asian patients (mean age 67 years) had a strikingly high 62% prevalence of diabetes. Conversely, rates of other co-morbidities such as AF were notably lower compared to Western cohorts ( lower age and low rates of obesity may explain the overall lower prevalence of AF in ASIAN-HF. This is consistent with our finding that the oldest Asian ethnic group of Japanese/Korean patients had the highest prevalence of AF among ethnicities; however, the rate of AF was paradoxically lowest in Indians, who had the highest rates of obesity and concentric LV hypertrophy. The particularly low prevalence of AF in Indians, both by medical history and on 72 (7) 67 (11) Men ( (7) 59 (9) 54 ( 77 (19) 76 (11) 79 (9) 78 ( 86.8 (22) 89 (22) 69 (10) 71 (10) 71 ( (7) 30 (5) 29 ( ECG, is consistent with prior reports from the Indian general population 15 and Indian patients with HF 25 as well as the small left atrial volumes on echocardiography. Previous data suggest that Indian ethnicity may be protective against developing AF; results from a community-based population from the UK showed that individuals from South Asian descent had a 70% lower risk for developing AF despite having a higher burden of risk factors. 30 Additionally, a seminal study on patients with HF (26% HFpEF) from the Trivandrum region in India showed that these patients have considerably low rates of AF. 31 Compared to Western registries (GWTG-HF, SWEDE-HF, ADHERE-HF, and OPTIMIZE-HF) and studies performed in primarily Western populations (TOPCAT; I-PRESERVE and CHARM-Preserved), Asian patients with HFpEF are almost a decade younger ( Table 5 ) compared to registries with Caucasian populations, while being of similar age to the TOPCAT and I-PRESERVE trials. Despite their relatively young age, Asian patients with HFpEF had a relatively high prevalence of co-morbidities, particularly CKD, diabetes and hypertension. Overall, prevalence of CAD was relatively low ( 34, 35 Regardless of the lower rates of obesity, diabetes was highly prevalent in our Asian HFpEF population. A prior study directly comparing population-based cohorts of Southeast Asian and Swedish patients with HF showed that diabetes was three-fold more common in Asian patients despite less obesity, and more strongly associated with poor outcomes in Asian patients than white patients. In fact, the prevalence of diabetes was almost 40% among Asian HF patients with BMI as low as ≤20 kg/m 2 , rising to >60% in those with BMI >30 kg/m 2 .
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Together with the data from our study, this suggests that in the case of obesity and HFpEF, metabolic derangement may play a key role in HFpEF, rather than pure mechanical load related to weight/obesity per se. This obese metabolic derangement seems to play a particular important role in Indian HFpEF patients, who had the lowest rates of all co-morbidities except for anaemia and obesity, yet the highest rates of concentric hypertrophy. The echocardiographic differences among ethnicities deserve mention. Almost all (99.5%) patients satisfied the 2016 ESC guidelines criteria for diastolic dysfunction, 20 providing important objective evidence for the validity of the HFpEF diagnosis. Furthermore, similarly high proportions of patients satisfied these diagnostic criteria across the entire cohort, with no difference among countries or across sites, consistent with uniform criteria used to diagnose HFpEF in the entire study. Asian patients with HFpEF had high rates of LVH compared to Western cohorts such as the Olmsted County, I-PRESERVE and PARAMOUNT populations. 37 39, 40 potentially related to younger age and less age-related remodelling in Asian patients. Difference in co-morbidity burden attenuated but could not fully account for the differences in LV remodelling among ethnicities, suggesting that ethnicity itself was an important determinant of LV geometry in HFpEF.
Overall outcome rates were better compared to data from Western patient populations with HFpEF from the OPTIMIZE-HF registry and the GWTG-HF registry (Table 5) . 28, 29 However, both the OPTIMIZE-HF and GWTG-HF registries included patients at hospitalization for acute HF or worsening of signs and symptoms of HF, suggesting that these populations were considerably sicker compared to the HFpEF population from ASIAN-HF. Nevertheless, overall outcomes in Asian HFpEF patients were closer to outcomes in key HFpEF trials such as TOPCAT, I-PRESERVE and CHARM-Preserved, which also included chronic HFpEF (Table 5) . 38, 41, 42 Among Asian patients with HFpEF, Southeast Asian patients with HFpEF had considerably worse outcomes compared to Northeast Asian patients. This confirms earlier separate reports from the Japanese CHART study and data from a Singaporean-based study, where mortality rates were 26% after 3 years and 27% after 2 years, respectively. 5, 8, 43 The consistency with prior single-nation studies from Asia suggests that the ASIAN-HF cohort is representative of HFpEF in these respective regions. Of note, a recent publication from the INTER-CHF registry, which included a majority of HFrEF patients, showed that Chinese HF patients had better outcomes compared to Southeast Asian HF patients, 44 which is in line with our findings for HFpEF. However, Indian patients performed markedly worse in the INTER-CHF study, which can be explained by the inclusion of patients in more rural areas compared to ASIAN-HF as well as the fact that the INTER-CHF registry included a majority of HFrEF patients. 44 
Limitations
There is a potential bias in site selection and willingness of patients to participate in a prospective registry. Site selection in ASIAN-HF was based on the size of the country, geographic location of the site within the country, patient population served, HF patient volume and availability of expertise in echocardiography. Priority was given to sites that could provide high quality data with as little missing data as possible. Given all the constraints of the large geographic areas with diverse socioeconomic factors and health care availability, our data represent the best practices prevalent in each country; thus, outcomes are expected to be even worse in the respective societies at large. Unfortunately, we did not have direct measurements of physical activity, which may be a confounder. Screening logs were encouraged but not available from all sites. Nevertheless, every effort was made to ensure protocol adherence and standardization including language translations specific to each region, on-site investigator training, regular monitoring (both in-person and remote), and centralized database management.
Conclusions
These first prospective multi-national data from Asia showed that Asian patients with HFpEF were relatively young (with more than a third under the age of 65 years) and lean (with only a fifth being obese), yet they carried a high co-morbidity burden (70% of patients had ≥2 co-morbidities). There were striking regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia. Southeast Asian patients had the highest prevalence of most co-morbidities, the most LVH and the worst outcomes. Among ethnicities, Malay patients with HFpEF had very high rates of obesity, diabetes, CKD and anaemia, and the worst outcomes among the ethnicities despite their relative youth. Compared to Western cohorts, Asian patients with HFpEF were considerably younger, yet had high prevalence of co-morbidities despite their relative youth. These regional and ethnic differences have important implications for public health measures and global HFpEF trial design.
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